Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China · Delayed Price · Currency is CNY 22.18
-1.90 (-7.89%)
Aug 21, 2026, 3:04 PM CST
SHE:300204 Revenue
Staidson (Beijing) BioPharmaceuticals had revenue of 46.90M CNY in the quarter ending March 31, 2026, a decrease of -25.81%. This brings the company's revenue in the last twelve months to 203.92M, down -30.42% year-over-year. In the year 2025, Staidson (Beijing) BioPharmaceuticals had annual revenue of 220.23M, down -32.20%.
Revenue (ttm)
203.92M
Revenue Growth
-30.42%
P/S Ratio
51.97
Revenue / Employee
415.31K
Employees
491
Market Cap
10.60B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 220.23M | -104.58M | -32.20% |
| Dec 31, 2024 | 324.82M | -39.36M | -10.81% |
| Dec 31, 2023 | 364.18M | -184.81M | -33.66% |
| Jan 1, 2023 | 548.99M | -35.30M | -6.04% |
| Dec 31, 2021 | 584.29M | 159.08M | 37.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Pacific Shuanglin Bio-pharmacy | 2.60B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Inner Mongolia Furui Medical Science | 1.63B |
| Jiangxi Fushine Pharmaceutical | 1.56B |
| Vcanbio Cell & Gene Engineering Corp., | 1.42B |
| Hualan Biological Vaccine | 1.20B |
| Chengdu Olymvax Biopharmaceuticals | 759.63M |